CVS Health will reinstate coverage for Eli Lilly’s GLP-1 injection Zepbound and add coverage for the new GLP-1 pill Foundayo.
This shift in coverage is significant because it could potentially open access to obesity and weight-loss treatments for millions of Americans [1]. By integrating these therapies into standard prescription drug plans, the company addresses a high-demand market for chronic weight management.
CVS Health and its pharmacy benefit manager, CVS Caremark, are moving to expand patient access to these specific therapies. The decision comes as demand for GLP-1 medications continues to rise across the U.S. healthcare system. The inclusion of Foundayo marks a transition toward providing non-injectable options for patients who may prefer a pill over an injection.
Zepbound had previously seen changes in its coverage status, but the company is now restoring it to preferred status. This move allows patients with eligible insurance plans to access the medication with lower out-of-pocket costs compared to non-covered alternatives.
The addition of Foundayo further diversifies the available treatment pathways. By offering both an injection and a pill, the provider aims to meet a wider range of patient needs, and clinical requirements for obesity treatment.
CVS Health said the move is intended to meet growing demand for GLP-1 therapies. The company is prioritizing the expansion of obesity and weight-loss treatment options to improve health outcomes for its members.
“CVS Health will reinstate coverage for Eli Lilly’s GLP-1 injection Zepbound.”
The reinstatement of Zepbound and the addition of Foundayo signal a broader industry trend where pharmacy benefit managers are reconciling the high cost of GLP-1 drugs with overwhelming patient demand. By expanding coverage, CVS Health is acknowledging that obesity treatment is increasingly viewed as a primary health necessity rather than an elective luxury, which may pressure other insurers to follow suit to remain competitive.
